نتایج جستجو برای: daclatasvir

تعداد نتایج: 714  

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013
Pablo Barreiro Eugenia Vispo Eva Poveda Jose V Fernández-Montero Vincent Soriano

The results from clinical trials testing new direct-acting antivirals (DAAs) for chronic hepatitis C were the major focus of interest at the 2012 annual meeting of the European Association for the Study of the Liver. Besides triple combinations, in which any one of the new DAAs is given along with peginterferon-α/ribavirin, clinical trials exploring interferon-free oral regimens combining sever...

2014
James H. Nettles Richard A. Stanton Joshua Broyde Franck Amblard Hongwang Zhang Longhu Zhou Junxing Shi Tamara R. McBrayer Tony Whitaker Steven J. Coats James J. Kohler Raymond F. Schinazi

Symmetric, dimeric daclatasvir (BMS-790052) is the clinical lead for a class of picomolar inhibitors of HCV replication. While specific, resistance-bearing mutations at positions 31 and 93 of domain I strongly suggest the viral NS5A as target, structural mechanism(s) for the drugs' activities and resistance remains unclear. Several previous models suggested symmetric binding modes relative to t...

Journal: :European journal of gastroenterology & hepatology 2015
Sabrina Trippoli Valeria Fadda Dario Maratea Andrea Messori

Fig. 1. (a) Estimates of SVR12 achievement, medians with 95% CrIs, calculated by the Bayesian model. The numerical values of these estimates are as follows: SOF/LED-12 weeks, 93.17 (95% CrI: 98.35–99.76); SOF/LED-8 weeks, 77.84 (95% CrI: 93.64–98.71); SOF/DAC, 87.62 (95% CrI: 99.56–100); ARIOD, 83.42 (95% CrI: 93.88–97.93); and ARIODR, 93.15 (95% CrI: 97.27–99.12). (b) Histograms of rankings es...

2017
Kazuo Tarao Akira Sato

Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/paritaprevir/ritonavir was also recommended as a therapy for HCV genotype 1b. More recently, elbasvir (NS5A inhibitor)/grazoprevir (NS3/4A protease inhi...

2015
Ruian Ke Claude Loverdo Hangfei Qi Ren Sun James O. Lloyd-Smith

Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies. Yet rapid evolution and high diversity of HCV populations, combined with the reality of suboptimal treatment adherence, make drug resistance a clinical and public health concern. We develop a general model incorporating viral dynamics and pharmacokin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید